换一批Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies.
第一作者：
Anna,Wawruszak
第一单位：
Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland.
作者：
医学主题词
抗衰老酶1(Sirtuin 1);人类(Humans);细胞增殖(Cell Proliferation);动物(Animals);斑马鱼(Zebrafish);紫杉酚(Paclitaxel);女(雌)性(Female);药物筛选试验, 抗肿瘤(Drug Screening Assays, Antitumor);细胞凋亡(Apoptosis);剂量效应关系, 药物(Dose-Response Relationship, Drug);分子结构(Molecular Structure);构效关系(Structure-Activity Relationship);组蛋白脱乙酰基酶抑制剂(Histone Deacetylase Inhibitors);抗肿瘤药(Antineoplastic Agents);细胞系, 肿瘤(Cell Line, Tumor);卡唑类(Carbazoles);肿瘤细胞, 培养的(Tumor Cells, Cultured);抗肿瘤药, 植物(Antineoplastic Agents, Phytogenic)
DOI
10.1080/14756366.2025.2458554
PMID
39935420
发布时间
2025-05-07
- 浏览2
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
